If I remember correctly in previous CC calls, TEVA has categorically said that they are very pleased with how their ANDA application is moving along with FDA for their generic version of Lovenox. If one would take this on face value, multiple approvals are more likely. Also would explain why Oppenheimer reluctance to raise their MNTA target significantly higher.
Market Data 
Markets 
AI
